Junevity raised $10M in seed funding led by Goldcrest Capital and Godfrey Capital to enhance its RESET platform for developing cell reset therapeutics for longevity.
PRIVATEFeb 13, 2025
Amount Raised
$10 Million
Round Type
Seed
San FranciscoBiotechnologyHealth CareGeneticsTherapeutics
Investors
Goldcrest CapitalGodfrey Capital
Description
Junevity, a biotechnology company focused on extending lifespan and healthspan, announced $10 million in seed funding. The funding will be used to enhance the RESET platform and develop therapeutic candidates targeting Type 2 diabetes, obesity, and frailty.
Company Information
Company
Junevity
Location
San Francisco, California, United States
About
Junevity is a longevity biotechnology company developing Cell Reset therapeutics. The RESET Platform is the first to use large-scale human data and AI to develop novel siRNA therapeutics targeting transcription factors. Founded out of UCSF in 2023, Junevity’s mission is to extend human lifespan and healthspan.
Fundz sees it the moment Junevity raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.